[Lu-177]-DOTATATE Injection (“[Lu-177]-DOTATATE”) is being studied for its safety and efficacy in the treatment of patients with neuroendocrine tumors (NETs). NETs are an uncommon and diverse group of cancers that arise from neuroendocrine cells, most often in the gastroenteropancreatic (GEP) tract or lungs. [Lu-177]-DOTATATE is a radiolabelled somatostatin analogue with high and specific affinity for somatostatin receptor subtype 2 (SSTR2); the characteristic overexpression of SSTRs in NETs forms the basis for peptide receptor radionuclide therapy (PRRT) with [Lu-177]-DOTATATE.
Clinical evidence suggests that [Lu-177]-DOTATATE may have utility to treat patients with locally advanced or metastatic NET disease, especially well-differentiated GEP-NETs
Ezziddin S, Khalaf F, Vanezi M et al. Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2014; 41(5):925-33.
Kwekkeboom DJ, de Herder WW, Kam BL et al. Treatment with the radiolabeled somatostatin analog 177Lu-DOTA-octreotate: toxicity, efficacy, and survival. J. Clin. Oncol.. 2008; 26(13): 2124-2130.
van Vliet EI, Teunissen JJ, Kam BL et al. Treatment of gastroenteropancreatic neuroendocrine tumors with peptide receptor radionuclide therapy. Neuroendocrinology. 2013; 97(1): 74-85.
Zaknun JJ, Bodei L, Mueller-Brand J et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013. 40: 800-816.
These references are provided for informational purposes only and do not represent an endorsement for any particular clinical use.
The safety and efficacy of [Lu-177]-DOTATATE Injection have not been fully established and it has not been approved by Health Canada as a commercial product for medicinal use. It is an investigational drug product and can only be used under an approved clinical trial application (CTA). Please contact the CPDC if you require further information.